Pluri Inc.

Equities

PLUR

US72942G2030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-09 pm EDT			5-day change	1st Jan Change
5.796 ^USD	+0.29%		+5.01%	+25.03%

Jul. 08	Pluri Inc. Announces ?1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply	CI
Jul. 02	Pluri Appoints Liat Zalts as CFO	MT

Plurinuva Ltd announced that it expects to receive $10 million in funding from Cfsc Investments, Inc., Interfonda AG, Tnuva Food-Tech Incubator, Limited Partnership, Pluri Biotech Ltd., Pluri Inc., and other investors

June 11, 2024

Plurinuva Ltd announced that it has signed a purchase agreement to issue ordinary shares for gross proceeds of $10,000,000 on June 12, 2024. The transaction will be co-led by new investors Cfsc Investments, Inc., Interfonda AG, Tnuva Food-Tech Incubator (2019), Limited Partnership, Pluri Biotech Ltd. The transaction will include participation from returning investor Pluri Inc. for $1,250,000, and such other persons or entities. Post completion of the transaction, Pluri Inc. will hold 69% stake in the company.

This has been approved in the board of directors of the company.

Latest news about Pluri Inc.

Pluri Inc. Announces ?1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply	Jul. 08	CI
Pluri Appoints Liat Zalts as CFO	Jul. 02	MT
Pluri Inc. Announces CFO Changes, Effective September 30, 2024	Jul. 02	CI
Pluri Inc. Announces Executive Changes, Effective September 30, 2024	Jul. 02	CI
Sector Update: Consumer Stocks Ease in Late Afternoon Trading	Jun. 18	MT
Sector Update: Consumer	Jun. 18	MT
Pluri's Ever After Foods Subsidiary Gets $10 Million Investment; Shares Rise	Jun. 18	MT
Plurinuva Ltd announced that it expects to receive $10 million in funding from Cfsc Investments, Inc., Interfonda AG, Tnuva Food-Tech Incubator, Limited Partnership, Pluri Biotech Ltd., Pluri Inc., and other investors	Jun. 11	CI
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.?s PLX-R18 Acute Radiation Syndrome Contract	Jun. 06	CI
Pluri Inc. Announces Strategic Collaboration with Wilk Technologies Ltd. to Develop Human Breast Milk-Derived Food Production on a Commercial Scale	May. 20	CI
Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 09	CI
Pluri Inc. Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment	May. 02	CI
Pluri Inc. Announces Appointments to Its Scientific Advisory Board	May. 02	CI
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08	MT
Sector Update: Health Care	Apr. 08	MT
Pluri Receives US Patent for Immune Cell Expansion	Apr. 08	MT
Pluri Inc. Unveils A Novel Method for Expansion of Immune Cells Using Proprietary Technology	Apr. 08	CI
Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing	Mar. 14	CI
Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation	Mar. 11	CI
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board	Mar. 06	CI
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 12	CI
Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis	Jan. 23	CI
Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division	Jan. 08	CI
Pluri Inc. Launches New Business Division Offering Cell Therapy Manufacturing Services as Contract Development and Manufacturing Organization: PluriCDMO	Jan. 08	CI
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction	Dec. 21	CI

Chart Pluri Inc.

Duration

Period

More charts

Company Profile

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Sector

Biotechnology & Medical Research

Calendar

2024-11-06 - Q1 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
PLURI INC.	+25.03%	31.24M
MODERNA, INC.	+16.71%	44.48B
LONZA GROUP AG	+42.66%	40.57B
IQVIA HOLDINGS INC.	-7.92%	38.82B
ALNYLAM PHARMACEUTICALS, INC.	+33.09%	32.22B
CELLTRION, INC.	-7.10%	27.84B
ICON PUBLIC LIMITED COMPANY	+14.46%	26.79B
UNITED THERAPEUTICS CORPORATION	+46.73%	14.31B
MEDPACE HOLDINGS, INC.	+34.07%	12.7B
BIO-TECHNE CORPORATION	-7.61%	11.23B

Other Biotechnology & Medical Research

Pluri Inc.

Equities

PLUR

US72942G2030

Biotechnology & Medical Research

Plurinuva Ltd announced that it expects to receive $10 million in funding from Cfsc Investments, Inc., Interfonda AG, Tnuva Food-Tech Incubator, Limited Partnership, Pluri Biotech Ltd., Pluri Inc., and other investors

Latest news about Pluri Inc.

Chart Pluri Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research